The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug Assistance Programs Offer Little Charity to Uninsured

Drug Assistance Programs Offer Little Charity to Uninsured

August 7, 2019 • By Lisa Rapaport

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—Many patients who receive assistance from charities set up to defray prescription drugs costs may already have insurance that covers most the cost for their medications, a U.S. study suggests.

You Might Also Like
  • U.S. Uninsured Rate Up by Most in Nearly a Decade
  • Americans Want Medicare to Help Negotiate Down Drug Prices
  • Drug Company Gifts Linked to Doctors’ Prescribing Habits

Researchers examined data on the six largest independent charities offering patient assistance programs through 274 different disease-specific programs. These programs had total revenue ranging from $24 million to $532 million and expenditures on patient assistance ranging from $24 million to $353 million in 2017.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Nearly all of the programs—97% of them—only helped patients with health insurance, typically by covering the cost of out-of-pocket expenses like co-payments or by contributing to premiums.

“The current findings show that they exclude people that do not have health insurance coverage, they cover almost every one of the people with health insurance [only the very wealthy do not qualify], and that the more expensive the drug the more likely it will be covered,” says Gerard Anderson of Johns Hopkins Bloomberg School of Public Health, Baltimore, senior author of the study.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Federal health programs, including Medicare and Medicaid, don’t allow pharmaceutical companies to sponsor drug-specific patient assistance programs for the medicines they make because this violates anti-kickback regulations, researchers note Aug. 6 online in JAMA.1 But federal rules still let companies financially support charities focused on diseases that are treated by drugs they sell.

In the study, researchers examined data on eight independent charity organizations that offer financial assistance to patients and had annual revenue of at least $10 million in 2017.

Overall, 61% of the charity organizations only offered patients help with co-payments, while another 33% allowed patients the option of getting help with co-pays or monthly insurance premiums. Another 3% of the programs only offered premium assistance.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Only 3% of the programs were limited to patients with annual income up to 300% of the federal poverty level, or $36,420 for an individual and $75,300 for a family of four. Another 43% of programs were open to people up to 400% of the poverty level, or $100,400 for a family of four; an additional 51% of programs covered people up to 500% of the federal poverty level, or 125,500 for a family of four.

The majority of these assistance programs covered diseases that are often treated with expensive injected drugs made from living cells. About 41% of the programs targeted cancer and 34% aided people with rare or genetic disorders.

The researchers didn’t know the actual dollar amounts disbursed to patients for specific drugs, or the amount of prescription drug use that was enabled by the programs. They also lacked data on any assistance decisions made for individual patients who applied for help.

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: drug access, Medicaid, Medicare, uninsured Americans

You Might Also Like:
  • U.S. Uninsured Rate Up by Most in Nearly a Decade
  • Americans Want Medicare to Help Negotiate Down Drug Prices
  • Drug Company Gifts Linked to Doctors’ Prescribing Habits
  • Healthcare Professionals Can Tap the ARP for Assistance

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)